Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd. operates as a clinical stage biotechnology company. It engages in the research and development of biotechnological and pharmaceutical products. The firm specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple Sclerosis, Crohn's disease and KRAS+ NSCLC. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

NEW YORK and LONDON, June 23, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization (CRO), to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe coronavirus disease 2019 (COVID-19) and pulmonary inflammation.

Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) has appointed a vice-president of regulatory affairs. Dr Kevin Shutz, who has 19 years pharma industry experience, 14 of them in the regulatory field, will lead clinical trial ‘interactions' with drug watchdogs in the US, Europe and Asia.

Tiziana Life Sciences appoints head of regulatory affairs

NEW YORK and LONDON, June 21, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment of Dr. Kevin Schutz, PharmD, as Vice-President of Regulatory Affairs. Dr. Schutz will lead regulatory interactions related to clinical studies in the United States, Europe and Asian countries.

Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs

The stock price of Tiziana Life Sciences PLC (NASDAQ: TLSA) increased by over 7% pre-market. This is why it happened.

TLSA Stock Price Increases Over 7% Pre-Market: Why It Happened

Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it applied for UK government funding for its nasally administered antibody therapy under a scheme looking for ‘take-home treatments' for sufferers of Coronavirus (COVID-19). Grants are being awarded to companies developing medicines that will prevent people with the illness from being hospitalised.

Tiziana Life Sciences seeks UK funding for 'take-home' nasal COVID-19 treatment

NEW YORK and LONDON, June 17, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases announces that it has submitted a grant to the United Kingdom COVID Therapeutics Advisory Panel (UK-CTAP) to support further clinical development of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, as an innovative ‘ Take Home' approach for treatment of non-hospitalized patients with COVID-19. This is in response to a call from the UK government for proposals to study therapies that can be delivered at home and avoid hospitalization of patients.

Tiziana Responds to UK Call for Development of Innovative ‘Take Home' Treatments for COVID-19 Disease

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting

Investment bank B Riley has restated its 'buy' advice and US$8 price target for shares in Tiziana Life Sciences PLC (LON:TILS) (NASDAQ:TLSA) after a flurry of positive news. It said safety data on key drug Foralumab, signs of its efficacy in COVID-19 patients and its clearance for its use in a patient with MS provided “incremental validation” of the monoclonal antibody (mAb) treatment.

US Investment bank repeats 'buy' and US$8 price target on Tiziana Life Sciences after flurry of positive news

Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR share, compared to a current price of US$2.37. It comes after Tiziana announced, on May 25, it had begun treating a first patient with secondary progressive multiple sclerosis (SPMS) in a trial using nasally administered Foralumab - its fully-human anti-CD3 monoclonal antibody.

Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS

Tiziana Life Sciences plc (NASDAQ: TLSA) has provided an update on further analysis of lymphocyte subsets from a Phase 1 study with nasally administered foralumab in healthy volunteers. Data showed statistically significant immunomodulatory effects on CD8 cytotoxic T-lymphocytes and other inflammatory biomarkers.

Tiziana Life's Foralumab Induces Immunomodulation, Anti-Inflammatory Effects In Early-Stage Study

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered nasally. The latest data come from a phase I assessment of Foralumab, which is being developed for a range of neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease.

Tiziana Life PLC hails "major accomplishment" as nasally administered antibody shows potential to treat degenerative diseases such as MS

NEW YORK and LONDON, May 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, today provided an update on further analysis of lymphocyte subsets from blood samples from a Phase 1 study with nasally administered Foralumab in healthy volunteers. Results exhibiting statistically significant immunomodulatory effects on CD8 cytotoxic T-lymphocytes and other inflammatory biomarkers were observed. This Phase 1 trial, conducted at the Brigham and Women's Hospital, Harvard Medical School, Boston, MA, was a single-site, double-blind, placebo-controlled, dose-ranging study with nasally administered Foralumab at 10, 50 and 250 mcg per day, consecutively for 5 days in healthy volunteers. The treatment was well-tolerated at all doses and there were no apparent symptoms of severe toxicity. Importantly, the treatment showed significant positive effects at 50 mcg/day dose (compared to other dose and placebo groups) on T-cell subsets and inflammatory biomarkers. These data support other clinical and pre-clinical studies showing that this route of administration is capable of inducing site-targeted immunomodulation and anti-inflammatory effects. Furthermore these pharmacodynamic data point to a clinical dose range that Tiziana intends to test in further clinical development among MS patients.

Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers

The stock price of Tiziana Life Sciences PLC (NASDAQ: TLSA) increased by over 8% pre-market. This is why it happened.

TLSA Stock Price: Over 8% Increase Pre-Market Explanation

Under an individual patient expanded access program, Tiziana Life Sciences plc (NASDAQ: TLSA) has dosed the first patient with secondary progressive multiple sclerosis with nasally administered foralumab. Nasal Foralumab 50 mcg (25 mcg/nostril) will be administered in 3-week cycles, three times/week dosing for the first two weeks followed by one week of a rest period.

Tiziana Life Starts Testing Nasally Administered Foralumab in Multiple Sclerosis Patients

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company's fully-human anti-CD3 monoclonal antibody. The drug will be provided under the Food & Drug Administration's individual patient expanded access protocol overseen by researchers at the Brigham and Women's Hospital (BWH), Harvard.

Tiziana Life Sciences initiates trial using nasally administered monoclonal antibody to treat a person with secondary progressive multiple sclerosis

NEW YORK and LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the first patient with secondary progressive multiple sclerosis (SPMS) was dosed with nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Women's Hospital (BWH), Harvard Medical School, Boston, MA. Nasal Foralumab 50 mcg (25 mcg/nostril) will be administered in 3-week cycles, with 3 times/week dosing for the first 2 weeks followed by 1 week of rest period. This first-ever clinical study in SPMS patients, under an Individual Patient Expanded Access IND, will continue for six months to evaluate routine safety, tolerability, and neurological behaviors. The study will also examine microglial activation, by positron emission tomography (PET), immunological and neurodegenerative markers to assess clinical responses following the treatment regimen.

Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Progr

Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) said it is confident that it is well positioned to advance its drug development programs "to their next respective value inflection points". Final results on Tuesday showed cash of £48.2mln in the bank at the end of December, after a year when the company made a loss before tax of £21.8mln as R&D and operating costs increased as it continued to progress a pipeline of drugs to treat rare cancers and autoimmune and inflammatory diseases.

Tiziana Life Sciences confident of advancing drug development pipeline

NEW YORK and LONDON, May 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with CEO and CSO Dr. Kunwar Shailubhai will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, May 8 at 7 p.m. local time. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in approximately 73M homes.

Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) announced an agreement with Takanawa Japan for a strategic business development plan to identify a clinical partner in Japan and other Asian countries. The pair are looking for a company to cooperate on further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients.

Tiziana Life Sciences seeks clinical partner in Asia to progress work on liver cancer treatment

NEW YORK and LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has executed an agreement with Takanawa Japan K.K, Pharma Team, (Takanawa) for a strategic business development plan to Identify a clinical partner in Japan and other Asian countries for further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients. HCC is the most common type of liver cancer and affects approximately 200,000 people per year.

Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.

Tiziana Life Sciences plc (LON:TILS NASDAQ:TLSA) said its former subsidiary, Accustem Sciences Limited intends to list on Nasdaq. The listing will follow shortly after the completion of the distribution of shares in Accustem to Tiziana's shareholders and reflects a belief by the directors that Nasdaq is the most appropriate market given the nature of Accustem's business.

Tiziana Life says breast cancer diagnostic business Accustem Sciences to list on Nasdaq

NEW YORK and LONDON, April 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited ("Accustem"), intends to file a listing application with the Nasdaq Stock Market shortly after completion of the distribution of shares in Accustem to Tiziana Life Sciences plc shareholders.

Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.

Zacks Small-Cap Research has started coverage on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which is advancing three candidates for a variety of indications in autoimmune disease, cancer and coronavirus (COVID-19). Zacks has placed a valuation of US$7.50 per ADR share compared to a current price of US$3 in New York (up over 12% on the day).

Zacks Small-Cap Research initiates coverage on Tiziana Life Sciences, which it expects to advance foralumab into "multiple clinical trials" this year

US investment bank B. Riley Financial has reiterated its ‘buy' advice and US$8 a share price target for Tiziana Life Sciences (NASDAQ:TLSA, LON:TILS) after a double dose of good news.

Tiziana Life Sciences: US investment bank restates its US$8 price and 'buy' recommendation after double dose of good news

The FDA has allowed evaluation of Tiziana Life Sciences Plc's (NASDAQ: TLSA) nasal administration with foralumab in a secondary progressive multiple sclerosis (SPMS) patient at the Brigham and Women's Hospital (BWH), Harvard University. The patient will be treated under an Individual Patient Expanded Access IND.

News for Tiziana Life Sciences Ltd Stock (TLSA)